Published on 19/12/2025
Requirements for CTD Submissions and Local Dossier Structure in Colombia (INVIMA)
As the pharmaceutical landscape expands globally, regulatory affairs in pharma have become increasingly significant. For companies looking to market their products in Colombia, an understanding of the requirements for CTD submissions and the local dossier structure is essential. This article provides a comprehensive step-by-step guide to navigate these regulatory pathways for effective market authorization in Colombia.
Step 1: Understanding the CTD Format
The Common Technical Document (CTD) format is an internationally recognized standard designed to facilitate the drug registration process. It streamlines submission to regulatory agencies globally, including Colombia’s National Institute for Food and Drug Surveillance (INVIMA). The CTD is divided into five modules:
- Module 1: Administrative information and prescribing information specific to the regional regulatory authority.
- Module 2: Summaries of the quality, non-clinical, and clinical data.
- Module 3: Quality data pertaining to the product.
- Module 4: Non-clinical study reports.
- Module 5: Clinical study reports.
To ensure compliance with ICH guidelines, each module must be prepared with precise documentation and data. For Module
Practical actions include gathering regulatory information, ensuring that all documents are compliant with Colombia’s legislative framework. Each submission must align with the regulations detailed in the INVIMA 2015 Resolution No. 1409, which outlines the registration process for pharmaceutical products.
Step 2: Preparing Local Dossier Structure
The local dossier structure for regulatory submissions to INVIMA must include relevant Colombian legislation. Understanding the local requirements is critical in aligning with national expectations. Information should be presented logically, following regional guidelines.
For Module 1, you will prepare the following documents:
- Cover Letter: Introduce the submission and the applicant, highlighting the type of application (new drug, generic, etc.).
- Application Form: Fill out the INVIMA-specific application form accurately.
- Product Labeling: Provide detailed product labeling, including packaging and insert, in Spanish.
- Good Manufacturing Practice (GMP) Certificate: Include valid GMP certification for manufacturing facilities, issued by recognized authorities.
Be meticulous about language and format as per INVIMA guidelines. Submissions must remain in Spanish, and non-compliance could lead to delays in the review process.
Step 3: Information on Quality, Non-Clinical, and Clinical Data
Modules 2 and 3 focus on comprehensive quality, non-clinical, and clinical data. This is where your pharmaceutical regulatory affairs team will need to ensure that the data is thorough, substantiated by credible studies, and well-presented. Here are actions to be taken:
Quality Data Preparation (Module 3)
For Module 3, consider the following:
- Quality Documentation: Ensure detailed information regarding the product’s formulation, manufacturing process validation, stability studies, and specifications.
- Raw Materials Documentation: List and validate all starting and excipient materials with their specifications.
- Analytical Method Validation: Include evidence of the validation of methods used for testing physical, chemical, and microbiological properties of the product.
The document must reflect the product’s compliance with the Colombian pharmacopoeia or any recognized pharmacopoeias.
Non-Clinical and Clinical Study Reports (Modules 4 and 5)
Ensure that:
- Study Designs: Describe the design, methodology, and results of non-clinical and clinical trials.
- Pharmacovigilance Considerations: Address safety data with adequate risk management measures and plans.
- Ethical Approval: Include proof of ethical approval from an Institutional Review Board (IRB) for all human studies.
Effective documentation will not only expedite approval but also align with global standards. Always refer to INVIMA’s official site for the most current guidelines and template formats.
Step 4: Submission Process and Acceptance of Dossier
The complete CTD submission should be carefully compiled following INVIMA’s submission guidelines. Once your dossiers are prepared, the next step is to submit them electronically to INVIMA through their E-Gestion platform.
Upon submission, the timeline for review starts. Currently, INVIMA has established internal guidelines to review documents within prescribed periods, typically ranging from 90 to 180 days, depending on the complexity of the submission.
- Electronic Submission Overview: Ensure all documents are submitted in PDF format, and ensure the structural integrity of the files before submission.
- Submission Receipt: Confirm the receipt of submission via the E-Gestion platform to track the review process.
During this phase, regulatory professionals must remain vigilant. Be prepared to respond promptly to any requests for additional information or clarification from INVIMA, which may occur during the review process.
Step 5: Addressing Requests for Additional Information
Post-submission, it is common for regulatory agencies to seek further information. This could stem from clarification on any trial data, quality certificates, or even labeling specifics. Here are some key considerations when addressing such requests:
- Act Promptly: Timeliness is crucial; a prompt and well-structured response can help expedite the review process.
- Thoroughness in Response: Provide comprehensive explanations, refer to data or studies as needed, and ensure that all questions from INVIMA are addressed in detail.
- Maintain Clarity: Ensure that responses are clear, professional, and devoid of ambiguity to minimize delays.
Engaging with INVIMA and ensuring clear communication can move your product toward approval more effectively. Regulatory teams must also keep internal notes on all interactions to ensure cohesive information flow and training for future submissions.
Step 6: Post-Approval Commitments and Ongoing Compliance
Once your product is approved, ongoing compliance is essential. Regulatory affairs professionals must ensure adherence to continuous monitoring and reporting standards. Key elements consist of:
- Pharmacovigilance Reporting: Establish a robust pharmacovigilance and risk management system to monitor product safety throughout its life cycle.
- Periodic Safety Update Reports (PSURs): Prepare and submit PSURs as dictated by INVIMA regulations, typically at specified intervals post-marketing.
- Quality Control Inspections: Be prepared for routine inspections to ensure that manufacturing practices comply with GMP standards.
Moreover, keep abreast of any regulatory changes in Colombia that may affect ongoing compliance. Keeping the local dossier up-to-date and renewing licenses as necessary will help maintain a seamless operational process for your pharmaceutical products in the market.
Conclusion
Understanding the complete regulatory pathway for pharmaceutical submissions to INVIMA is crucial for successful market access in Colombia. Each step from CTD format understanding, dossier preparation, to submission and post-approval commitments requires thorough attention to detail and adherence to regulations. By following the outlined steps and maintaining compliance with local guidelines, regulatory affairs professionals can effectively navigate the complexities of pharmaceutical regulatory affairs.
For additional information and details on regulations, always refer to the official resources provided by INVIMA and related authorities.